Experts Agree Jardiance Reduces Cardiac Deaths
June 29, 2016 — Late yesterday, expert advisors to the FDA voted by a margin of 12-11 that the diabetes drug Jardiance (emagliflozin) does indeed cut the risk of cardiovascular deaths for patients with type 2 diabetes who have a history of cardiovascular disease. The committee was unanimous in its agreement that the drug offers good cardiovascular safety. But […]
